Zacks Research Issues Negative Forecast for Hologic Earnings

Hologic, Inc. (NASDAQ:HOLX) – Investment analysts at Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for Hologic in a report released on Tuesday, December 31st. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings per share of $1.01 for the quarter, down from their prior forecast of $1.02. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. Zacks Research also issued estimates for Hologic’s Q2 2025 earnings at $1.06 EPS, FY2025 earnings at $4.28 EPS, Q1 2026 earnings at $1.12 EPS, Q2 2026 earnings at $1.14 EPS, Q4 2026 earnings at $1.20 EPS, FY2026 earnings at $4.63 EPS, Q1 2027 earnings at $1.12 EPS and FY2027 earnings at $4.99 EPS.

HOLX has been the topic of several other research reports. Royal Bank of Canada lifted their price objective on Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a report on Tuesday, November 5th. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research report on Thursday, December 19th. JPMorgan Chase & Co. raised their target price on shares of Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. BNP Paribas upgraded shares of Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Finally, Wolfe Research began coverage on shares of Hologic in a report on Friday, December 13th. They issued a “peer perform” rating on the stock. Six analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Hologic has an average rating of “Moderate Buy” and a consensus target price of $89.50.

Hologic Stock Performance

NASDAQ:HOLX opened at $73.19 on Friday. The company has a market capitalization of $16.61 billion, a price-to-earnings ratio of 21.98, a PEG ratio of 2.32 and a beta of 0.96. The business has a 50 day moving average of $76.72 and a 200 day moving average of $78.44. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. Hologic has a 1-year low of $70.36 and a 1-year high of $84.67.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same period in the previous year, the business earned $0.89 EPS. The business’s revenue for the quarter was up 4.5% on a year-over-year basis.

Insider Activity

In other news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.75% of the company’s stock.

Hedge Funds Weigh In On Hologic

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Andra AP fonden lifted its position in Hologic by 224.5% during the second quarter. Andra AP fonden now owns 95,400 shares of the medical equipment provider’s stock valued at $7,083,000 after purchasing an additional 66,000 shares during the period. GAMMA Investing LLC raised its stake in shares of Hologic by 17.9% during the 3rd quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider’s stock valued at $312,000 after buying an additional 582 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Hologic by 2.9% in the 3rd quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock valued at $2,344,000 after buying an additional 800 shares during the period. Quest Partners LLC grew its holdings in Hologic by 56.1% during the second quarter. Quest Partners LLC now owns 41,492 shares of the medical equipment provider’s stock worth $3,081,000 after acquiring an additional 14,914 shares during the period. Finally, Versor Investments LP acquired a new stake in Hologic during the third quarter worth about $1,677,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.